Resmed (RMD) EBITDA (2009 - 2026)

Resmed has reported EBITDA for 18 years, with the latest figure at $499.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 17.25% year-over-year to $499.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 17.4% YoY), and the FY2025 full-year result was $1.8 billion, up 27.57% from the prior year.
• EBITDA for Q1 2026 stood at $499.8 million, up from $491.7 million in the prior quarter.
• The five-year high for EBITDA was $499.8 million in Q1 2026, with the low at $234.3 million in Q1 2022.
• Historically, EBITDA has averaged $356.8 million across 5 years, with a median of $374.6 million in 2024.
• Annual changes were most pronounced in 2023 — EBITDA dropped 1.82% — and 2024, when it jumped 51.67%.
• Resmed's EBITDA stood at $280.2 million in 2022, then slipped by 1.82% to $275.1 million in 2023, then jumped by 51.67% to $417.2 million in 2024, then gained by 17.84% to $491.7 million in 2025, then rose by 1.66% to $499.8 million in 2026.
• The last three EBITDA figures came in at $499.8 million (Q1 2026), $491.7 million (Q4 2025), and $446.5 million (Q3 2025), per Business Quant data.